Skip to content

A Randomized Controlled Trial of Tintidikadi Lepa Followed by Til Tail Padabhyanga in maids w.s.r to Padadari

A Randomized Controlled Trial of Tintidikadi Lepa Followed by Til Tail Padabhyanga in Maids w.s.r to Padadari - Nil

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/08/093358
Enrollment
80
Registered
2025-08-20
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L749- Eccrine sweat disorder, unspecified

Interventions

None listed

Sponsors

Dr Vishnu Namdev walwate
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Individuals having Age Group 25-50 years 2.Individuals having any 2 or more samanya Lakshanas of padadari out of following Padasfutan Vedana Rukshata Daha kandu 3.Irrespective of education religion and socio economic status 4.Individuals willing for regular follow up.

Exclusion criteria

Exclusion criteria: 1.Individuals having Diabetes, Psoriasis, Athletes foot. 2.Individuals Suffering from Skin disorder like Hyperkeratotic eczema. 3.Individuals having history of burn.

Design outcomes

Primary

MeasureTime frame
1.To the effect of Tintidikadi Lepa with til tail padabhyanga on Evaluation of heel skin by specially grading scale. 2.To the effect of Haritaki Lepa on Evaluation of heel skin by specially grading scale. 3.To compare effect of Tintidikadi Lepa on Evaluation of heel skin by specially grading scale. Timepoint: 7 15 30 days

Secondary

MeasureTime frame
1.To study the literature about Padadari according to Ayurved and Modern science. 2.To study the literature of Tintidika,Guda ,Lavan ,Goomutra, Ghrita ,Til tail in Ayurveda and Modern science. Timepoint: 1 year

Countries

India

Contacts

Public ContactDr.Vishnu Namdev Walwate

GAC Nagpur

manjiri.palnitkar@gmail.com9657526630

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026